{"id":"SCV000884146","rcv_accession_id":"RCV000428048","submission_id":"25969.2019-08-05","version":"2","clinical_assertion_observation_ids":["SCV000884146.0"],"internal_id":"1730401","date_created":"2019-02-15","local_key":"74380|MedGen:CN169374","submitter_id":"25969","variation_id":"3520","trait_set_id":"9590","submission_names":["Aug 2019 ARUP"],"interpretation_comments":[],"review_status":"criteria provided, single submitter","submitted_assembly":"not applicable","variation_archive_id":"VCV000003520","clinical_assertion_trait_set_id":"SCV000884146","interpretation_description":"Uncertain significance","content":"{\"AttributeSet\":{\"Attribute\":{\"$\":\"ARUP Molecular Germline Variant Investigation Process\",\"@Type\":\"AssertionMethod\"},\"Citation\":{\"URL\":{\"$\":\"https://submit.ncbi.nlm.nih.gov/ft/byid/jucit10y/arup_molecular_germline_variant_investigation_process.pdf\"}}}}","assertion_type":"variation to disease","interpretation_date_last_evaluated":"2018-07-13","record_status":"current","date_last_updated":"2020-02-10"}
{"id":"SCV001144884","rcv_accession_id":"RCV000727222","submission_id":"1012.2019-09-25","version":"1","clinical_assertion_observation_ids":["SCV001144884.0"],"internal_id":"2256633","date_created":"2020-01-16","local_key":"2853148|not provided","submitter_id":"1012","variation_id":"46503","trait_set_id":"9460","submission_names":["SUB6347501"],"interpretation_comments":[],"review_status":"criteria provided, single submitter","submitted_assembly":"GRCh37","variation_archive_id":"VCV000046503","clinical_assertion_trait_set_id":"SCV001144884","interpretation_description":"Likely benign","content":"{\"AttributeSet\":{\"Attribute\":{\"$\":\"Athena Diagnostics Criteria\",\"@Type\":\"AssertionMethod\"},\"Citation\":{\"ID\":{\"$\":\"26467025\",\"@Source\":\"PubMed\"}}},\"Interpretation\":{\"Citation\":{\"ID\":{\"$\":\"27208204\",\"@Source\":\"PubMed\"}}}}","assertion_type":"variation to disease","interpretation_date_last_evaluated":"2019-03-14","record_status":"current","date_last_updated":"2020-01-20"}
{"id":"SCV000266006","rcv_accession_id":"RCV000210085","submission_id":"506834.2016-03-03","version":"1","clinical_assertion_observation_ids":["SCV000266006.0","SCV000266006.1","SCV000266006.2","SCV000266006.3","SCV000266006.4","SCV000266006.5","SCV000266006.6","SCV000266006.7","SCV000266006.8"],"internal_id":"498299","date_created":"2016-03-19","local_key":"c.3920T\u003eA","submitter_id":"506834","variation_id":"822","trait_set_id":"1570","submission_names":["GIM_BROCA"],"interpretation_comments":["{\"text\":\"Low penetrance mutation that is associated with a small increase in risk of colon cancer and with an increased risk of colon polyps (Boursi 2013)\"}"],"review_status":"criteria provided, single submitter","submitted_assembly":"GRCh37","variation_archive_id":"VCV000000822","clinical_assertion_trait_set_id":"SCV000266006","interpretation_description":"risk factor","content":"{\"AttributeSet\":{\"Attribute\":{\"$\":\"Shirts et al. (Genet Med 2016)\",\"@Type\":\"AssertionMethod\"},\"Citation\":{\"ID\":{\"$\":\"26845104\",\"@Source\":\"PubMed\"}}},\"ClinVarSubmissionID\":{\"@localKeyIsSubmitted\":\"1\"}}","assertion_type":"variation to disease","interpretation_date_last_evaluated":"2015-11-20","record_status":"current","date_last_updated":"2020-02-15"}
{"id":"SCV000604327","rcv_accession_id":"RCV001000015","submission_id":"25969.2019-08-05","version":"3","clinical_assertion_observation_ids":["SCV000604327.0"],"internal_id":"1168023","date_created":"2017-09-27","local_key":"118047|MedGen:CN169374","submitter_id":"25969","variation_id":"42540","trait_set_id":"9590","submission_names":["Aug 2019 ARUP"],"interpretation_comments":["{\"text\":\"The p.Arg502Trp variant (rs375882485) is a well-known causative variant reported in multiple individuals with hypertrophic cardiomyopathy (HCM; Richard 2003, Maron 2008, Kaski 2012, and Lopez 2013), and shown to segregate with disease in at least one affected family (Camuglia 2013). In one large study, the p.Arg502Trp variant was identified in 2.4% of Caucasian HCM patients (Saltzman 2010). This variant was also found at 1.4% in 6179 individuals diagnosed with HCM (Walsh 2017). Nuclear magnetic resonance studies indicate that p.Arg502Trp may impair important electrostatic interactions between MYBPC3 protein and other sarcomeric proteins (Zhang 2014). Thus, the p.Arg502Trp variant meets our criteria for classification as pathogenic.\"}"],"review_status":"criteria provided, single submitter","submitted_assembly":"not applicable","variation_archive_id":"VCV000042540","clinical_assertion_trait_set_id":"SCV000604327","interpretation_description":"Pathogenic","content":"{\"AttributeSet\":{\"Attribute\":{\"$\":\"ARUP Molecular Germline Variant Investigation Process\",\"@Type\":\"AssertionMethod\"},\"Citation\":{\"URL\":{\"$\":\"https://submit.ncbi.nlm.nih.gov/ft/byid/jucit10y/arup_molecular_germline_variant_investigation_process.pdf\"}}}}","assertion_type":"variation to disease","interpretation_date_last_evaluated":"2019-04-07","record_status":"current","date_last_updated":"2020-02-10"}
